Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 7/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041656 | 0.96 | TNK2 (0.41) | TNK2WEE1PTK2SRCCDK4 | |
| SCHEMBL16309176 | 0.93 | TNK2 (0.40) | TNK2WEE1SRCPLK2CDK4 | |
| SCHEMBL10192630 | 0.82 | CDK4 (0.47) | PTK2SRCCDK4FGFR1CCND1 | |
| SCHEMBL13553639 | 0.82 | TNK2 (0.42) | TNK2WEE1PTK2SRCCDK4 | |
| SCHEMBL15036080 | 0.81 | CDK4 (0.41) | TNK2SRCCDK4CCND1 | |
| SCHEMBL15041503 | 0.79 | TNK2 (0.43) | TNK2SRC | |
| SCHEMBL15036092 | 0.78 | BRD4 (0.48) | TNK2WEE1PTK2CDK4EGFR | |
| SCHEMBL10246428 | 0.76 | WEE1 (0.44) | TNK2WEE1PTK2RIPK2ACVR1 | |
| SCHEMBL15036139 | 0.76 | TNK2 (0.44) | TNK2WEE1SRCBRD4 | |
| SCHEMBL14866053 | 0.76 | WEE1 (0.43) | TNK2WEE1PTK2CDK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | TNK2 14/4885WEE1 1354/4885PTK2 137/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885WEE1 545/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.